Home › Funds › Lynx1 Capital Management LP › AVTX
Lynx1 Capital Management LP position in AVTX
AVALO THERAPEUTICS INC · Health Care
Lynx1 Capital Management LP reported holding 10,100 shares of AVTX (AVALO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$155K, representing 0.02% of its reported portfolio and ranking #26 among its reported holdings. Lynx1 Capital Management LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Lynx1 Capital Management LP's AVTX position evolved
Lynx1 Capital Management LP first disclosed a stake in AVTX in Q2 2026 at 10,100 shares (US$187K). Across 2 filings, Lynx1 Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 10,100 shares valued at US$155K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 10.10K | $186.65K | New |
| Q3 2026 | 10.10K | $154.83K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in AVTX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$60.9M), Deep Track Capital, LP (US$55.3M), Caligan Partners LP (US$50.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- FARALLON CAPITAL MANAGEMENT, L.L.C. 3.97M sh · $60.92M · Q3 2026
- Deep Track Capital, LP 3.61M sh · $55.34M · Q3 2026
- Caligan Partners LP 3.27M sh · $50.10M · Q3 2026
- Affinity Asset Advisors, LLC 3.24M sh · $49.74M · Q3 2026
- TCG Crossover Management, LLC 3.02M sh · $46.25M · Q3 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.38M sh · $36.45M · Q3 2026
- Nantahala Capital Management, LLC 2.14M sh · $32.84M · Q3 2026
- BRAIDWELL LP 1.61M sh · $24.67M · Q3 2026
- Logos Global Management LP 1.50M sh · $23.00M · Q3 2026
- Trails Edge Capital Partners, LP 1.50M sh · $23.00M · Q3 2026
- Commodore Capital LP 1.02M sh · $15.61M · Q3 2026
More on Lynx1 Capital Management LP
FAQ
How long has Lynx1 Capital Management LP held AVTX?
Lynx1 Capital Management LP has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Lynx1 Capital Management LP's current position in AVTX?
As of Q3 2026, Lynx1 Capital Management LP holds 10.10K shares of AVTX (AVALO THERAPEUTICS INC), valued at $154.83K, representing 0.02% of its reported portfolio and ranking #26.
Has Lynx1 Capital Management LP been buying or selling AVTX?
In the latest 13F filing (Q3 2026), Lynx1 Capital Management LP held unchanged its position in AVTX.
Which other funds hold AVTX?
Other major institutional holders of AVTX include FARALLON CAPITAL MANAGEMENT, L.L.C., Deep Track Capital, LP, Caligan Partners LP, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.